I'd strongly recommend taking a look at NWBO, if I'm right their potential may be unlimited as they use the cancer and white cells from the patient to create a vaccine that's specific to that patient. They proved the concept in GBM, one of the toughest cancers, and at UCLA they combined it with Poly-ICLC and/or Keytruda and have taken 5 year survival to 50% or more. The SOC has 5% survival, and the vaccine alone achieved 13%, but the other therapeutics don't work without being combined with the vaccine.
Under compassionate use in the UK several patients with different cancers were treated, and while it's just anecdotal evidence, it's enough for the company to openly say it's a tumor agnostic vaccine. On GBM approval alone the stock should go into double digit prices in a year or so, but with a tumor agnostic label, just move the decimal point a couple or more to the right, if it isn't bought out.
The vaccine has virtually no negative side effects, but in GBM, and perhaps all the other solid cancers it increases T-cell counts dramatically in the cancer, so your own T-cells are fighting your cancer.
There are many bashers casting doubt on the trial, but I believe the regulators have been involved, and accepted all the changes and approvals will come, perhaps with confirming trials required in the future. No doubt there will be several trials post approval to expand the label to truly tumor agnostic.
By the way, I'm really not that certain that the Institutions will agree to the buyout price, ABBV's estimate that sales for Elahere should reach $2 billion a year may tell the Institution's that this price is already too low, and it's not providing any real value to IMGN's extensive pipeline and partnerships.
Gary
